REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel ...
Jasper Therapeutics, Inc. announced promising results from its BEACON Phase 1b/2a study of briquilimab, an antibody therapy targeting mast cell diseases like chronic spontaneous urticaria (CSU). In ...
Jasper Therapeutics, Inc. ( (JSPR)) has released its Q2 earnings. Here is a breakdown of the information Jasper Therapeutics, Inc. presented to its investors. Take advantage of TipRanks Premium at 50% ...
Newsflash: As of 8 a.m. this morning, a BURN BAN is in effect! This past week I, along with my staff attended the National ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback